Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 91.8%

Neg 0% Neu 0% Pos 91.8%

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.